Prof. Marcy Zenobi-Wong is a Full Professor at ETH Zurich's Department of Health Sciences and Technology, specializing in biofabrication and tissue engineering. Her research focuses on cartilage regeneration using advanced biomaterials, including nanofilm coatings and 3D printing techniques. She holds patents in tissue engineering and has pioneered methods like filamented light (FLight) biofabrication for creating anisotropic tissues. Her academic journey includes a B.Sc. from MIT (1985), M.Sc. and Ph.D. from Stanford (1987, 1990), followed by postdoctoral work at the University of Michigan. She leads the Biofabrication Group at ETH, developing therapies for joint repair and regenerative medicine. Courses taught include Biomedical Engineering and Materials and Mechanics in Medicine . Research highlights include engineered hydrogels for cartilage protection, CRISPR-driven gene editing in chondrocytes, and biohybrid neural interfaces. Her work bridges material science, cell biology, and clinical applications, with a focus on translational medicine. Collaborative projects involve creating elastic cartilage grafts for microtia reconstruction and volumetric printing of complex tissue constructs.
John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.
Michel M. Maharbiz is a Professor in the Department of Electrical Engineering and Computer Science at the University of California, Berkeley. He leads research on miniaturized bioelectronic interfaces, including neural dust implants and cyborg insects. He holds affiliations with the Berkeley Sensor & Actuator Center (BSAC), Center for Neural Engineering & Prostheses (CNEP), and SWARM Lab. His education includes a Ph.D. in EECS from UC Berkeley (2003) and a B.S. in EE from Cornell University (1997). Maharbiz's research integrates MEMS, ultrasonic systems, and synthetic biology to develop wireless neural interfaces, implantable sensors, and biohybrid devices. Key focus areas are neural dust technology for peripheral nerve recording, magnetoelastic strain sensors for medical applications, and electrochemical biosensing using bacterial flagellar motors. His publications emphasize neural interfaces, ultrasonic implants, and biomedical monitoring. Recent articles explore ultrasonic power delivery (2025), radiation detectors for oncology (2025), and fracture-healing smart plates (2019). Trends include miniaturization of wireless implants, closed-loop therapeutic systems, and novel biomaterials. Scientific Awards: McKnight Technological Innovations in Neuroscience Award (2017) Chan-Zuckerberg Biohub Investigator (2017) NSF CAREER Award (2009) MIT TR10 Top Emerging Technology (2009) Bakar Fellows Spark Award (2012) He directs the Maharbiz Lab, advancing neural dust and bioelectronic interfaces. Projects include impedance-based fracture monitoring, carbon fiber neural arrays, and hernia repair sensors. Funding includes NSF and industry partnerships for implantable device development.
Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Paul O'Toole is a Professor of Microbial Genomics and Principal Investigator at the APC Microbiome Ireland, University College Cork. His research focuses on the gut microbiome's role in health, aging, and disease, particularly in the context of diet and probiotics. He leads projects like the ELDERMET study on elderly nutrition and the NU-AGE project exploring Mediterranean diets' anti-aging effects. He holds a BA (Mod.) from Trinity College Dublin and a PhD from Lund University, with postdoctoral training in Canada and New Zealand. Key grants include studies on dairy-derived microbiota, probiotic strain improvement, and microbiome analysis in aging populations. He has published extensively on Lactobacillus genomics, gut-brain interactions, and microbiome-driven health outcomes. His work bridges fundamental microbiology with clinical applications, emphasizing translational research. Scientific highlights include discovering microbiome links to cognitive decline, demonstrating dietary modulation of gut microbes to combat obesity, and identifying keystone species in healthy aging. He advocates for sustainability in conservation and food systems, reflecting his interdisciplinary approach to global health challenges.
Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Carina Mallard is Professor of Experimental Perinatal Brain Injury Research and Pro-Vice-Chancellor at the University of Gothenburg since July 2023, where she oversees research infrastructure and chairs the Research Board. She previously served as Deputy Vice-Chancellor (2021–2023) and Head of Core Facilities (2018–2021). Her academic career began with a Physiology degree from Lund University and a PhD in Pediatrics at the University of Auckland (1995), followed by a professorship appointment in 2006. Her research focuses on perinatal brain injury , particularly in premature infants , investigating neuroinflammatory mechanisms maternal dietary interventions neurovascular unit dynamics microglia activation long-term consequences of maternal obesity . Recent publications highlight her work on neonatal rodent models , transcriptomic profiling , and anti-inflammatory therapies . Key themes include RNA degradation , mitochondrial protection , and immune-neurovascular interactions . She has supervised 20 doctoral students since 2004 and collaborates internationally with institutions like King's College London. Contact details include two institutional emails and physical addresses across Gothenburg's biomedical campuses. Her leadership roles span research strategy, doctoral education, and EU-level scientific initiatives.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Nonappa Nonappa is an Associate Professor (tenure track) in Nanochemistry at Tampere University's Faculty of Engineering and Natural Sciences since 2020. With a multidisciplinary background spanning organic chemistry, supramolecular systems, nanoparticle self-assembly, and advanced electron microscopy, he leads research at the intersection of materials science and biomedical applications. PhD in Organic Chemistry (IISc Bangalore, 2008) Docent in Soft Matter Microscopy (Aalto University, 2017) Executive MBA (Quantic School, 2020) Research focuses on bio-based optical materials using nanocellulose for sustainable photonics, breast cancer models via lab-on-a-chip systems, and precision nanomaterials through tailored self-assembly mechanisms. His team develops 3D extracellular matrices for cancer tissue culture and plasmonic nanodevices for photonic applications. Recent publications highlight gold/silver nanocluster assemblies (43+ citations in 2021-2025), electron tomography for structural analysis, and metastasis modeling systems. Key awards include Italy's Abilitazione Scientifica Nazionale (2018) and Aalto University's Docent title (2017).
Priya Raman, Ph.D., FCVS, is an Associate Professor of Integrative Medical Sciences at Northeast Ohio Medical University (NEOMED). She holds tenure and serves as Co-Director of the Basic and Translational Biomedicine (BTB) Graduate Program and Chair of the Kent State University-Biomedical Sciences Pharmacology Graduate Program. Her academic roles include teaching in NEOMED’s medical curriculum, focusing on pharmacology, cardiovascular systems, and clinical therapeutics. Raman’s research explores molecular mechanisms linking metabolic disorders (e.g., diabetes, metabolic syndrome) to vascular dysfunction and Alzheimer’s disease, using mouse models and cellular/molecular techniques. She has published extensively on thrombospondin-1, O-GlcNAc signaling, and atherosclerosis pathogenesis. Education: B.Pharm. and M.Pharm. (India), Ph.D. in Pharmacology (University of Louisiana at Monroe). She has over 25 years of postdoctoral and faculty experience, including roles at the Cleveland Clinic and Indiana University School of Medicine. Raman serves on editorial boards for journals like International Journal of Cardiology and Frontiers in Cardiovascular Medicine , and reviews grants for the American Heart Association and NIH. Research focus areas include: (1) Vascular smooth muscle cell phenotypic switching in metabolic diseases, (2) Non-lipid mechanisms of vascular disease in metabolic syndrome, and (3) Interactions between metabolic disorders and neurodegeneration. Her lab employs biochemical assays, mouse models (e.g., ApoE-/-, KKAy), and advanced imaging techniques to study these pathways. Notable recent work includes discovering that O-GlcNAc transferase deletion reduces atherosclerosis in hyperglycemic mice and identifying thrombospondin-1’s role in leptin-driven vascular pathology. She has also linked metabolic syndrome-induced O-GlcNAc deficits to Alzheimer’s-like cognitive impairment in aging mice. Raman is actively involved in interprofessional education and mentoring, directing graduate programs and teaching courses in pharmacology, molecular signaling, and diabetes/vascular disease. Her work bridges basic science and clinical applications, aiming to develop novel therapies for metabolic syndrome-related vascular complications.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
